Mefloquine targets NLRP3 to reduce lipopolysaccharide‐induced systemic inflammation and neural injury.

MLA

Jiang, Si‐Yuan, et al. “Mefloquine Targets NLRP3 to Reduce Lipopolysaccharide‐induced Systemic Inflammation and Neural Injury.” EMBO Reports, vol. 24, no. 10, Oct. 2023, pp. 1–15. EBSCOhost, https://doi.org/10.15252/embr.202357101.

APA

Jiang, S., Tian, T., Li, W., Liu, T., Wang, C., Hu, G., Du, R., Liu, Y., & Lu, M. (2023). Mefloquine targets NLRP3 to reduce lipopolysaccharide‐induced systemic inflammation and neural injury. EMBO Reports, 24(10), 1–15. https://doi.org/10.15252/embr.202357101

Chicago

Jiang, Si‐Yuan, Tian Tian, Wen‐Jie Li, Ting Liu, Cong Wang, Gang Hu, Ren‐Hong Du, Yang Liu, and Ming Lu. 2023. “Mefloquine Targets NLRP3 to Reduce Lipopolysaccharide‐induced Systemic Inflammation and Neural Injury.” EMBO Reports 24 (10): 1–15. doi:10.15252/embr.202357101.